The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists

• Conditions: Rheumatoid Arthritis; Crohn's Disease; Ankylosing Spondylitis; Psoriasis

• Registration Number: NCT00224562
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.

Detailed Description

Not available

Study Timeline

• Status Verified: 2004-02
• Study Start: 2004-02
• Study First Submitted: 2005-09-14
• Study First Submitted QC: 2005-09-14
• Study First Posted: 2005-09-23
• Last Update Submitted: 2005-10-25
• Last Update Posted: 2005-10-26

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

• none

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

All French departments of rheumatology, internal medicine, gastro-enterology, dermatology, infectious diseases, intensive care unit, oncology and haematology, paediatrics and chest medicine; 🇫🇷 All Cities, France